Save information for later
Sign Up

Learn About Olivopontocerebellar Atrophy

What is the definition of Olivopontocerebellar Atrophy?
Olivopontocerebellar atrophy (OPCA) is a term used for a progressive condition characterized by the degeneration of nerve cells (neurons) in specific areas of the brain. OPCA can be viewed as a finding of several diseases, and indicates a form of progressive ataxia (abnormal or uncontrolled movements) distinguished by characteristic findings in brain imaging studies and at autopsy (pontine flattening and cerebellar atrophy). It was traditionally divided in hereditary or genetic OPCA and sporadic OPCA. Currently, most of the major forms of hereditary OPCA refer to disorders that overlap with spinocerebellar ataxia (SCA), which is a neurological disorder characterized by ataxia. The sporadic forms are considered now to be a form of multiple system atrophy (MSA). OPCA may also occur in people with prion disorders and inherited metabolic diseases. The main symptom is clumsiness that slowly gets worse. Other symptoms may include problems with balance; speech or swallowing problems; difficulty walking; abnormal eye movements; muscle spasms; and neuropathy. Whether OPCA is inherited (and the inheritance pattern) depends on the underlying cause, if known.
What are the alternative names for Olivopontocerebellar Atrophy?
  • Olivopontocerebellar atrophy
  • OPCA
Who are the top Olivopontocerebellar Atrophy Local Doctors?
Distinguished in Olivopontocerebellar Atrophy
Distinguished in Olivopontocerebellar Atrophy

University Of Cincinnati Physicians Company LLC

3188 Bellevue Ave, 
Cincinnati, OH 
 (8.4 mi)
Languages Spoken:
English, Spanish
Accepting New Patients
Offers Telehealth

Alberto Espay is a Neurologist in Cincinnati, Ohio. Dr. Espay and is rated as a Distinguished provider by MediFind in the treatment of Olivopontocerebellar Atrophy. His top areas of expertise are Parkinson's Disease, Drug Induced Dyskinesia, Focal Dystonia, Conversion Disorder, and Deep Brain Stimulation. Dr. Espay is currently accepting new patients.

Advanced in Olivopontocerebellar Atrophy
Advanced in Olivopontocerebellar Atrophy

University Of Cincinnati Physicians Company LLC

3113 Bellevue Ave, 
Cincinnati, OH 
 (9.1 mi)
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Cara Jacob is a Neurologist in Cincinnati, Ohio. Dr. Jacob and is rated as an Advanced provider by MediFind in the treatment of Olivopontocerebellar Atrophy. Her top areas of expertise are Parkinson's Disease, Drug Induced Dyskinesia, Focal Dystonia, and Corticobasal Degeneration. Dr. Jacob is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Experienced in Olivopontocerebellar Atrophy
Internal Medicine
Experienced in Olivopontocerebellar Atrophy
Internal Medicine

Trihealth H LLC

379 Dixmyth Ave, 
Cincinnati, OH 
 (9.0 mi)
Languages Spoken:
English, German
Accepting New Patients

Paula Lafranconi is an Internal Medicine provider in Cincinnati, Ohio. Dr. Lafranconi and is rated as an Experienced provider by MediFind in the treatment of Olivopontocerebellar Atrophy. Her top areas of expertise are Familial Combined Hyperlipidemia, Xanthoma, Cirrhosis, and Type 2 Diabetes (T2D). Dr. Lafranconi is currently accepting new patients.

What are the latest Olivopontocerebellar Atrophy Clinical Trials?
Natural History of Spinocerebellar Ataxia Type 7 (SCA7)

Background: Spinocerebellar ataxia type 7 (SCA7) is a disease in which people have problems with coordination, balance, speech and vision. It is caused by a change in the ATXN7 gene. A mutation in this ATXN7 gene causes changes in eye cells, which can lead to vision loss. There is no cure for SCA7 but researchers are looking for possible treatments. Researchers need more information about SCA7. They want to c...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1 Placebo-Controlled Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-ATXN2 in Adult Subjects With Spinocerebellar Ataxia Type 2

Summary: Adult participants with spinocerebellar ataxia type 2 (SCA2) who carry ≥33 cytosine, adenine, guanine (CAG) repeats in the ATXN2 gene, and who have met all protocol eligibility criteria will be randomized to receive a single dose of ARO-ATXN2 or placebo and be evaluated for safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) parameters.

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center